Table 1. Characteristics of the NSCLC cell lines used in this study.
NSCLC cell line | Histology | EGFR status | KRAS or LKB1 mutation | P53 mutation | IC50s of Gefitinib (μM) |
---|---|---|---|---|---|
HCC4006 | AD | del E746–A750, amplification | no | no | 0.25 |
NCI-H1975 | AD | L858R and T790M | no | R273H | >20 |
HCC95 | SCC | wild-type | no | no | >20 |
NCI-H2122 | AD | wild-type | KRAS (G12C), LKB1(P281fs*6) | Q16L, C176F | >10 |
NCI-H3122 | AD | wild-type | EML4/ALK (E13;A20) | E285V | >10 |
AD, adenocarcinoma; SCC, squamous cell carcinoma.